Mark Bolland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7403356/publications.pdf

Version: 2024-02-01

272	13,507	31976	24258
papers	citations	53 h-index	110 g-index

282	282	282	12162
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ: British Medical Journal, 2010, 341, c3691-c3691.	2.3	931
2	Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ: British Medical Journal, 2011, 342, d2040-d2040.	2.3	740
3	Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ: British Medical Journal, 2008, 336, 262-266.	2.3	585
4	Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet, The, 2014, 383, 146-155.	13.7	497
5	A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. European Journal of Endocrinology, 2008, 159, 89-95.	3.7	409
6	The Peroxisome Proliferator-Activated Receptor-Î³ Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1305-1310.	3.6	399
7	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes and Endocrinology,the, 2014, 2, 307-320.	11.4	371
8	Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone, 2007, 41, 318-320.	2.9	332
9	Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ: British Medical Journal, 2017, 359, j4849.	2.3	320
10	Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. Lancet Diabetes and Endocrinology,the, 2018, 6, 847-858.	11.4	303
11	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1174-1181.	3.6	285
12	Fracture Prevention with Zoledronate in Older Women with Osteopenia. New England Journal of Medicine, 2018, 379, 2407-2416.	27.0	280
13	Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ, The, 2015, 351, h4183.	6.0	272
14	Randomized Controlled Trial of Calcium in Healthy Older Women. American Journal of Medicine, 2006, 119, 777-785.	1.5	249
15	Calcium and vitamin D supplements and health outcomes: a reanalysis of the Womenâ€™s Health Initiative (WHI) limited-access data set. American Journal of Clinical Nutrition, 2011, 94, 1144-1149.	4.7	243
16	Calcium intake and risk of fracture: systematic review. BMJ, The, 2015, 351, h4580.	6.0	241
17	Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis , , ,. American Journal of Clinical Nutrition, 2014, 100, 746-755.	4.7	229
18	Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1525-1530.	3.6	183

#	Article	IF	Citations
19	The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. American Journal of Clinical Nutrition, 2007, 86, 959-964.	4.7	173
20	Evaluation of the FRAX and Garvan fracture risk calculators in older women. Journal of Bone and Mineral Research, 2011, 26, 420-427.	2.8	158
21	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 569-576.	11.4	151
22	Mortality and morbidity in Cushingâ€™s syndrome in New Zealand. Clinical Endocrinology, 2011, 75, 436-442.	2.4	149
23	Vitamin D supplementation and falls: a trial sequential meta-analysis. Lancet Diabetes and Endocrinology,the, 2014, 2, 573-580.	11.4	149
24	Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone, 2006, 38, 317-321.	2.9	126
25	Randomized Controlled Trial of Calcium Supplementation in Healthy, Nonosteoporotic, Older Men. Archives of Internal Medicine, 2008, 168, 2276.	3.8	122
26	Determinants of vitamin D status in older women living in a subtropical climate. Osteoporosis International, 2005, 16, 1641-1648.	3.1	121
27	Annual Zoledronate Increases Bone Density in Highly Active Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Men: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1283-1288.	3.6	119
28	Vitamin D insufficiency and health outcomes over 5 y in older women. American Journal of Clinical Nutrition, 2010, 91, 82-89.	4.7	119
29	Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4522-4528.	3.6	118
30	The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women. Osteoporosis International, 2007, 18, 479-486.	3.1	115
31	Effect of calcium supplementation on hip fractures. Osteoporosis International, 2008, 19, 1119-1123.	3.1	111
32	The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia, 2015, 58, 2238-2246.	6.3	104
33	Calcium supplements: benefits and risks. Journal of Internal Medicine, 2015, 278, 354-368.	6.0	101
34	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 538-544.	3.6	100
35	Effects of a Î²-Blocker on Bone Turnover in Normal Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5212-5216.	3.6	97
36	Circulating calcium concentrations, vascular disease and mortality: a systematic review. Journal of Internal Medicine, 2016, 279, 524-540.	6.0	97

#	Article	IF	Citations
37	Cardiovascular effects of calcium supplementation. Osteoporosis International, 2011, 22, 1649-1658.	3.1	93
38	Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology, 2016, 87, 2391-2402.	1.1	92
39	Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. American Journal of Clinical Nutrition, 2010, 91, 131-139.	4.7	91
40	Cushing's Syndrome Due to Interaction Between Inhaled Corticosteroids and Itraconazole. Annals of Pharmacotherapy, 2004, 38, 46-49.	1.9	90
41	Skeletal Effects of Interventions in Mild Primary Hyperparathyroidism: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1653-1662.	3.6	85
42	Relationships between vascular calcification, calcium metabolism, bone density, and fractures. Journal of Bone and Mineral Research, 2010, 25, 2777-2785.	2.8	83
43	Five years of anti-resorptive activity after a single dose of zoledronate â€" Results from a randomized double-blind placebo-controlled trial. Bone, 2012, 50, 1389-1393.	2.9	83
44	Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. British Journal of Nutrition, 2013, 110, 1384-1393.	2.3	81
45	Calcium and Cardiovascular Disease. Endocrinology and Metabolism, 2017, 32, 339.	3.0	75
46	Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. Journal of Bone and Mineral Research, 2010, 25, 505-512.	2.8	74
47	Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clinical Endocrinology, 2007, 67, 259-264.	2.4	73
48	Delayed Development of Paget's Disease in Offspring InheritingSQSTM1Mutations. Journal of Bone and Mineral Research, 2007, 22, 411-415.	2.8	73
49	Does calcium supplementation increase cardiovascular risk?. Clinical Endocrinology, 2010, 73, 689-695.	2.4	73
50	Determinants of vitamin D status in older men living in a subtropical climate. Osteoporosis International, 2006, 17, 1742-1748.	3.1	70
51	Stable Bone Density in HAART-Treated Individuals with HIV: A Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2721-2731.	3.6	68
52	Check for publication integrity before misconduct. Nature, 2020, 577, 167-169.	27.8	64
53	Prolonged antiresorptive activity of zoledronate: A randomized, controlled trial. Journal of Bone and Mineral Research, 2010, 25, 2251-2255.	2.8	57
54	Role of ultrasound in the assessment of nodular thyroid disease. Journal of Medical Imaging and Radiation Oncology, 2009, 53, 177-187.	1.8	55

#	Article	IF	Citations
55	Calcium supplements and cardiovascular risk: 5 years on. Therapeutic Advances in Drug Safety, 2013, 4, 199-210.	2.4	55
56	Calcium supplementation in osteoporosis: useful or harmful?. European Journal of Endocrinology, 2018, 178, D13-D25.	3.7	55
57	Decreased bone density in men on methadone maintenance therapy. Addiction, 2011, 106, 349-354.	3.3	53
58	Differences in Overlapping Meta-Analyses of Vitamin D Supplements and Falls. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4265-4272.	3.6	53
59	Paget disease of bone. Trends in Endocrinology and Metabolism, 2008, 19, 246-253.	7.1	52
60	Unhelpful information about adverse drug reactions. BMJ, The, 2014, 349, g5019-g5019.	6.0	52
61	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1922-1928.	3.6	50
62	Mendelian Randomization Analysis to Examine for a Causal Effect of Urate on Bone Mineral Density. Journal of Bone and Mineral Research, 2015, 30, 985-991.	2.8	50
63	Bone mineral density remains stable in HAART-treated HIV-infected men over 2Âyears. Clinical Endocrinology, 2007, 67, 270-275.	2.4	49
64	Clinical Trial Evidence and Use of Fish Oil Supplements. JAMA Internal Medicine, 2014, 174, 460.	5.1	49
65	Trials of Vertebroplasty for Vertebral Fractures. New England Journal of Medicine, 2009, 361, 2097-2100.	27.0	47
66	Paget's disease of bone: clinical review and update. Journal of Clinical Pathology, 2013, 66, 924-927.	2.0	47
67	A Case Study of Discordant Overlapping Meta-Analyses: Vitamin D Supplements and Fracture. PLoS ONE, 2014, 9, e115934.	2.5	47
68	Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clinical Endocrinology, 2006, 65, 191-197.	2.4	45
69	The effect of treatments for osteoporosis on mortality. Osteoporosis International, 2013, 24, 1-6.	3.1	45
70	Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis?. Climacteric, 2015, 18, 22-31.	2.4	44
71	The effects of seasonal variation of 25-hydroxyvitamin D on diagnosis of vitamin D insufficiency. New Zealand Medical Journal, 2008, 121, 63-74.	0.5	44
72	Pioglitazone increases bone marrow fat in type 2 diabetes: results from a randomized controlled trial. European Journal of Endocrinology, 2012, 166, 1087-1091.	3.7	43

#	Article	IF	Citations
73	Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 286-292.	3.6	43
74	Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?. Osteoporosis International, 2014, 25, 2347-2357.	3.1	43
75	Controversies in medicine: the role of calcium and vitamin D supplements in adults. Medical Journal of Australia, 2019, 211, 468-473.	1.7	43
76	Calcium and/or Vitamin D Supplementation for the Prevention of Fragility Fractures: Who Needs It?. Nutrients, 2020, 12, 1011.	4.1	43
77	Effects of Intravenous Zoledronate on Bone Turnover and BMD Persist for at Least 24 Months. Journal of Bone and Mineral Research, 2008, 23, 1304-1308.	2.8	41
78	Reporting of Limitations of Observational Research. JAMA Internal Medicine, 2015, 175, 1571.	5.1	39
79	Role of vitamin D deficiency in cardiovascular disease. Heart, 2012, 98, 609-614.	2.9	38
80	The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. European Journal of Endocrinology, 2014, 170, 255-262.	3.7	37
81	Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporosis International, 2015, 26, 499-503.	3.1	37
82	Disparate Outcomes from Applying U.K. and U.S. Osteoporosis Treatment Guidelines. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1856-1860.	3.6	36
83	Calcium supplements: bad for the heart?. Heart, 2012, 98, 895-896.	2.9	36
84	Skeletal health in adults with HIV infection. Lancet Diabetes and Endocrinology,the, 2015, 3, 63-74.	11.4	36
85	An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature. BMJ Open, 2019, 9, e031909.	1.9	36
86	Calcium supplementation: Balancing the cardiovascular risks. Maturitas, 2011, 69, 289-295.	2.4	34
87	Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial. Cmaj, 2017, 189, E1130-E1136.	2.0	34
88	Randomised controlled trial of vitamin D supplementation in sarcoidosis. BMJ Open, 2013, 3, e003562.	1.9	33
89	Antioxidant supplements for preventing gastrointestinal cancers. , 2004, , CD004183.		31
90	Antiretroviral Preexposure Prophylaxis for HIV Prevention. New England Journal of Medicine, 2013, 368, 82-84.	27.0	31

#	Article	IF	Citations
91	Calcium riskâ€“benefit updatedâ€”New WHI analyses. Maturitas, 2014, 77, 1-3.	2.4	31
92	Citation of retracted publications: A challenging problem. Accountability in Research, 2022, 29, 18-25.	2.4	31
93	A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ Open, 2014, 4, e005787.	1.9	30
94	Cardiovascular Complications of Calcium Supplements. Journal of Cellular Biochemistry, 2015, 116, 494-501.	2.6	30
95	Discrepancies in predicted fracture risk in elderly people. BMJ, The, 2013, 346, e8669-e8669.	6.0	28
96	Should adults take vitamin D supplements to prevent disease?. BMJ, The, 2016, 355, i6201.	6.0	28
97	Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1641-e1647.	3.6	28
98	Heterophile antibodies may cause falsely lowered serum cortisol values. Journal of Endocrinological Investigation, 2005, 28, 643-645.	3.3	27
99	Web of industry, advocacy, and academia in the management of osteoporosis. BMJ, The, 2015, 351, h3170.	6.0	27
100	Assessment of research waste part 2: wrong study populations- an exemplar of baseline vitamin D status of participants in trials of vitamin D supplementation. BMC Medical Research Methodology, 2018, 18, 101.	3.1	27
101	The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. Rheumatology, 2008, 48, 195-197.	1.9	26
102	Evolution of Paget's disease of bone in adults inheriting <scp>SQSTM</scp>1 mutations. Clinical Endocrinology, 2015, 83, 315-319.	2.4	26
103	The Auckland calcium study: 5-year post-trial follow-up. Osteoporosis International, 2014, 25, 297-304.	3.1	25
104	Stable bone mineral density over 6â€ƒyears in HIVâ€infected men treated with highly active antiretroviral therapy (HAART). Clinical Endocrinology, 2012, 76, 643-648.	2.4	24
105	Meta-analysis of randomised trials comparing a penicillin or cephalosporin with a macrolide or lincosamide in the treatment of cellulitis or erysipelas. Infection, 2016, 44, 607-615.	4.7	23
106	Quality of reports of investigations of research integrity by academic institutions. Research Integrity and Peer Review, 2019, 4, 3.	5.2	23
107	Bone Formation Markers in Adults with Mild Osteogenesis Imperfecta. Clinical Chemistry, 2007, 53, 1109-1114.	3.2	22
108	Calcium supplementation and vascular disease. Climacteric, 2008, 11, 280-286.	2.4	22

#	Article	IF	Citations
109	Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2014, 29, 166-172.	2.8	21
110	Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. BMJ, The, 2016, 354, i5109.	6.0	21
111	Antiâ€fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial. Journal of Internal Medicine, 2019, 286, 221-229.	6.0	21
112	Results of Observational Studies: Analysis of Findings from the Nursesâ€™ Health Study. PLoS ONE, 2014, 9, e110403.	2.5	21
113	The impact of dietary calcium intake and vitamin D status on the effects of zoledronate. Osteoporosis International, 2013, 24, 349-354.	3.1	20
114	Low-dose Fluoride in Postmenopausal Women: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2301-2307.	3.6	20
115	A case of low cortisol-binding globulin: use of plasma free cortisol in interpretation of hypothalamic-pituitary-adrenal axis tests. Annals of Clinical Biochemistry, 2006, 43, 237-239.	1.6	19
116	Does degree of baldness influence vitamin D status?. Medical Journal of Australia, 2008, 189, 674-675.	1.7	19
117	We read spam a lot: prospective cohort study of unsolicited and unwanted academic invitations. BMJ, The, 2016, 355, i5383.	6.0	19
118	Reporting of conflicts of interest in oral presentations at medical conferences: a delegate-based prospective observational study. BMJ Open, 2017, 7, e017019.	1.9	19
119	Rounding, but not randomization method, non-normality, or correlation, affected baseline P-value distributions in randomized trials. Journal of Clinical Epidemiology, 2019, 110, 50-62.	5.0	18
120	Gastrointestinal stromal tumour in succinate dehydrogenase subunit B mutation-associated familial phaeochromocytoma/paraganglioma. ANZ Journal of Surgery, 2006, 76, 763-764.	0.7	17
121	Differences between self-reported and verified adverse cardiovascular events in a randomised clinical trial. BMJ Open, 2013, 3, e002334.	1.9	16
122	Baseline P value distributions in randomized trials were uniform for continuous but not categorical variables. Journal of Clinical Epidemiology, 2019, 112, 67-76.	5.0	16
123	Empirically generated reference proportions for baseline p values from rounded summary statistics. Anaesthesia, 2020, 75, 1685-1687.	3.8	16
124	Bilateral Femoral Head Osteonecrosis After Septic Shock and Multiorgan Failure. Journal of Bone and Mineral Research, 2003, 19, 517-520.	2.8	15
125	Testosterone Levels Following Decreases in Serum Osteocalcin. Calcified Tissue International, 2013, 93, 133-136.	3.1	15
126	Subgroup analysis for the risk of cardiovascular disease with calcium supplements. BoneKEy Reports, 2013, 2, 293.	2.7	15

#	Article	IF	Citations
127	Management recommendations for osteoporosis in clinical guidelines. Clinical Endocrinology, 2016, 84, 687-692.	2.4	15
128	Time for a moratorium on vitamin D meta-analyses?. BMJ: British Medical Journal, 2009, 339, b4394-b4394.	2.3	15
129	Trials of vertebroplasty for vertebral fractures. New England Journal of Medicine, 2009, 361, 2098-9; author reply 2099-100.	27.0	15
130	Artifact in the control group undermines the conclusions of a vitamin D and cancer study. American Journal of Clinical Nutrition, 2008, 87, 792-792.	4.7	14
131	Calcium Supplements Increase Risk of Myocardial Infarction. Journal of Bone and Mineral Research, 2015, 30, 389-390.	2.8	14
132	Assessing and Raising Concerns About Duplicate Publication, Authorship Transgressions and Data Errors in a Body of Preclinical Research. Science and Engineering Ethics, 2020, 26, 2069-2096.	2.9	14
133	Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies. European Journal of Clinical Nutrition, 2022, 76, 196-205.	2.9	14
134	Bone Mineral Density and Bone Turnover 10â€‰Years After a Single 5â€‰mg Dose or Two 5-Yearly Lower Doses of Zoledronate in Osteopenic Older Women: An Open-Label Extension of a Randomized Controlled Trial. Journal of Bone and Mineral Research, 2020, 37, 3-11.	2.8	14
135	Familial Paget Disease and SQSTM1 Mutations in New Zealand. Calcified Tissue International, 2011, 89, 258-264.	3.1	13
136	Calcium Supplements and Fracture Prevention. New England Journal of Medicine, 2014, 370, 386-388.	27.0	13
137	Bone density is normal and does not change over 2Âyears in sarcoidosis. Osteoporosis International, 2015, 26, 611-616.	3.1	13
138	Do vitamin D supplements help prevent respiratory tract infections?. BMJ: British Medical Journal, 2017, 356, j456.	2.3	13
139	Randomised trial assessing the impact of framing of fracture risk and osteoporosis treatment benefits in patients undergoing bone densitometry. BMJ Open, 2017, 7, e013703.	1.9	13
140	Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men. Journal of Bone and Mineral Research, 2019, 34, 1248-1253.	2.8	13
141	Timeliness and content of retraction notices for publications by a single research group. Accountability in Research, 2022, 29, 347-378.	2.4	13
142	Media Coverage, Journal Press Releases and Editorials Associated with Randomized and Observational Studies in High-Impact Medical Journals: A Cohort Study. PLoS ONE, 2015, 10, e0145294.	2.5	13
143	Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report. Annals of Clinical Microbiology and Antimicrobials, 2008, 7, 3.	3.8	12
144	Bilateral Transient Osteoporosis of the Hip in a Young Man. Journal of Clinical Densitometry, 2008, 11, 339-341.	1.2	12

#	Article	IF	Citations
145	Calcium supplementation and cancer incidence. American Journal of Clinical Nutrition, 2008, 87, 792-793.	4.7	12
146	Conflicts of interest and expertise of independent commenters in news stories about medical research. Cmaj, 2017, 189, E553-E559.	2.0	11
147	Publication rates after the first retraction for biomedical researchers with multiple retracted publications. Accountability in Research, 2019, 26, 277-287.	2.4	11
148	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	7.4	10
149	Calcium Supplements and Risk of Myocardial Infarction: An Hypothesis Twice Tested. American Journal of Medicine, 2012, 125, e15.	1.5	10
150	Correcting the scientific record â€“ A broken system?. Accountability in Research, 2021, 28, 265-279.	2.4	10
151	Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Womenâ€™s Health Initiative Limited-Access Dataset. PLoS ONE, 2015, 10, e0139975.	2.5	10
152	Response to publication of PRISM trial. Journal of Bone and Mineral Research, 2010, 25, 1463-1464.	2.8	9
153	Misclassification does not explain increased cardiovascular risks of calcium supplements. Journal of Bone and Mineral Research, 2012, 27, 959-959.	2.8	9
154	Comment on Kanis et al.: Pitfalls in the external validation of FRAX. Osteoporosis International, 2013, 24, 389-390.	3.1	9
155	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2014, 2, 364-365.	11.4	9
156	Assessment of research waste part 1: an exemplar from examining study design, surrogate and clinical endpoints in studies of calcium intake and vitamin D supplementation. BMC Medical Research Methodology, 2018, 18, 103.	3.1	9
157	Re: The calcium scare: what would Austin Bradford Hill have thought?. Osteoporosis International, 2011, 22, 3079-3080.	3.1	8
158	Calcium supplements and cardiovascular risk. Journal of Bone and Mineral Research, 2011, 26, 899-899.	2.8	8
159	Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate. Journal of Bone and Mineral Research, 2020, 36, 61-66.	2.8	8
160	Vitamin D supplementation and testing in the UK: costly but ineffective?. BMJ, The, 2021, 372, n484.	6.0	8
161	Calcium supplements and cardiovascular risk. Nature Reviews Cardiology, 2012, 9, 497-498.	13.7	7
162	Calcium Intake and Cardiovascular Disease Risk. Annals of Internal Medicine, 2017, 166, 684.	3.9	7

#	Article	IF	Citations
163	Further major uncorrected errors in National Osteoporosis Foundation meta-analyses of calcium and vitamin D supplementation in fracture prevention. Osteoporosis International, 2017, 28, 733-734.	3.1	7
164	A randomised investigation of journal responses to academic and journalist enquiry about possible scientific misconduct. BMC Research Notes, 2018, 11, 521.	1.4	7
165	25-Hydroxyvitamin D â€“ Should labs be measuring it?. Annals of Clinical Biochemistry, 2019, 56, 188-189.	1.6	7
166	Participant withdrawals were unusually distributed in randomized trials with integrity concerns: a statistical investigation. Journal of Clinical Epidemiology, 2021, 131, 22-29.	5.0	7
167	Vitamin D Dose Requirements for Fracture Prevention. New England Journal of Medicine, 2012, 367, 1367-1370.	27.0	6
168	Press Releases Issued by Supplements Industry Organisations and Non-Industry Organisations in Response to Publication of Clinical Research Findings: A Case-Control Study. PLoS ONE, 2014, 9, e101533.	2.5	6
169	Nitrates Do Not Affect Bone Density or Bone Turnover in Postmenopausal Women: A Randomized Controlled Trial. Journal of Bone and Mineral Research, 2020, 35, 1040-1047.	2.8	6
170	Clinical trial registry documents and publication integrity. Accountability in Research, 2021, 28, 149-161.	2.4	6
171	Authors' response to editorial. BMJ: British Medical Journal, 2011, 342, d3520-d3520.	2.3	5
172	Errors in NOF meta-analyses of calcium and vitamin D supplements. Osteoporosis International, 2016, 27, 2637-2639.	3.1	5
173	Identical summary statistics were uncommon in randomized trials and cohort studies. Journal of Clinical Epidemiology, 2021, 136, 180-188.	5.0	5
174	Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective. New Zealand Medical Journal, 2006, 119, U2339.	0.5	5
175	A randomized trial alerting authors, with or without coauthors or editors, that research they cited in systematic reviews and guidelines has been retracted. Accountability in Research, 2024, 31, 14-37.	2.4	5
176	Effect of calcium supplementation on hip fractures: reply to correspondence. Osteoporosis International, 2009, 20, 835-836.	3.1	4
177	Calcium supplements and cardiovascular risk in the Womenâ€™s Health Initiative. Osteoporosis International, 2013, 24, 2371-2372.	3.1	4
178	Vitamin D supplements do not reduce mortality risk. BMJ, The, 2014, 348, g2860-g2860.	6.0	4
179	Inconsistent data in text and tables. Osteoporosis International, 2015, 26, 2713-2713.	3.1	4
180	Vitamin D Supplements and the Risk of Falls. JAMA Internal Medicine, 2015, 175, 1723.	5.1	4

#	Article	IF	Citations
181	Concerns About the Integrity of Sato etÂal. Am J Med. 2005;118:1250-1255. American Journal of Medicine, 2018, 131, e107-e108.	1.5	4
182	Concerns About the Integrity of the Yamaguchi Osteoporosis Prevention Study (YOPS) Report, Am J Med. 2004;117:549-555. American Journal of Medicine, 2020, 133, e311-e314.	1.5	4
183	Prevalence of biochemical osteomalacia in adults undergoing vitamin D testing. Clinical Endocrinology, 2021, 95, 74-83.	2.4	4
184	Prospective 10-year study of postmenopausal women with asymptomatic primary hyperparathyroidism. New Zealand Medical Journal, 2008, 121, 18-29.	0.5	4
185	Prevalent dietary supplement use in older New Zealand men. New Zealand Medical Journal, 2011, 124, 55-62.	0.5	4
186	Evidence From Randomized Controlled Trials, Meta-analyses, and Subgroup Analyses. JAMA - Journal of the American Medical Association, 2010, 303, 1253.	7.4	3
187	Calcium supplements and cardiovascular disease - picking the spin. International Journal of Clinical Practice, 2011, 65, 226-227.	1.7	3
188	Fracture-risk calculators: Has their time come?. Cmaj, 2011, 183, 171-172.	2.0	3
189	Vitamin D testing. Lancet, The, 2012, 379, 1699.	13.7	3
190	Vitamin D and health in adults in Australia and New Zealand: a position statement. Medical Journal of Australia, 2012, 197, 553-553.	1.7	3
191	A pooled analysis of Vitamin D dose requirements for fracture prevention. IBMS BoneKEy, 2013, 10, .	0.0	3
192	Strontium and cardiovascular events. Annals of the Rheumatic Diseases, 2013, 72, e22-e22.	0.9	3
193	An inappropriate response?. BMJ, The, 2013, 346, f942-f942.	6.0	3
194	Vitamin and Mineral Supplements in the Primary Prevention of Cardiovascular Disease and Cancer. Annals of Internal Medicine, 2014, 160, 655.	3.9	3
195	Different outcomes of meta-analyses and data inconsistency: response to comments by Pfeifer. Archives of Osteoporosis, 2015, 10, 43.	2.4	3
196	Vitamin D supplements do not prevent falls. BMJ, The, 2016, 353, i3005.	6.0	3
197	Cessation of strontium ranelate supply. BMJ: British Medical Journal, 2017, 357, j2580.	2.3	3
198	Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals. Trials, 2018, 19, 592.	1.6	3

#	Article	IF	Citations
199	Long-Term Stable Bone Mineral Density in HIV-Infected Men Without Risk Factors for Osteoporosis Treated with Antiretroviral Therapy. Calcified Tissue International, 2019, 105, 423-429.	3.1	3
200	Vitamin D supplementation and musculoskeletal health â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 88-89.	11.4	3
201	"Cherry picking" did not occur in studied example. BMJ: British Medical Journal, 2010, 341, c5009-c5009.	2.3	3
202	The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. New Zealand Medical Journal, 2007, 120, U2804.	0.5	3
203	Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand?. New Zealand Medical Journal, 2012, 125, 83-91.	0.5	3
204	Translation of research into clinical practice: a case study of calcium supplement prescribing in New Zealand. New Zealand Medical Journal, 2014, 127, 94-101.	0.5	3
205	Outcomes of bone density measurements in coeliac disease. New Zealand Medical Journal, 2016, 129, 40-4.	0.5	3
206	Diversity of invited speakers at endocrinology conferences. Clinical Endocrinology, 2022, 96, 907-913.	2.4	3
207	Calcium supplementation for older men and women?. Osteoporosis International, 2009, 20, 2147-2148.	3.1	2
208	Is calcium supplementation a risk factor for cardiovascular diseases in older women?. Nutrition Reviews, 2009, 67, 424-424.	5.8	2
209	Effect of Osteoporosis Treatment on Mortality: A Meta-Analysis. Obstetrical and Gynecological Survey, 2010, 65, 514-515.	0.4	2
210	Vitamin D Supplementation. Archives of Internal Medicine, 2010, 170, 572.	3.8	2
211	Vitamin D testing. Lancet, The, 2012, 379, 1699-1700.	13.7	2
212	Vitamin D and tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3528-E3528.	7.1	2
213	Calcium supplements associated with increased risk of cardiovascular death in men but not women. Evidence-based Nursing, 2014, 17, 90-90.	0.2	2
214	Review: Dietary or supplemental calcium increase BMD by â‰Â1.8% in persons >Â50 years of age. Annals of Internal Medicine, 2016, 164, JC5.	3.9	2
215	News coverage of clinical research. BMJ, The, 2016, 352, i1177.	6.0	2
216	Inaccurate dissemination of the MAVIDOS trial results. Lancet Diabetes and Endocrinology,the, 2016, 4, 481.	11.4	2

#	Article	IF	Citations
217	Qualitative research, observational research, andThe BMJ. BMJ, The, 2016, 352, i1483.	6.0	2
218	Revised Meta-analysis of Vitamin K and Fractures. JAMA Internal Medicine, 2018, 178, 1135.	5.1	2
219	Inaccurate retraction notice for meta-analysis by Iwamoto et al. Acta Neurologica Scandinavica, 2018, 138, 263-263.	2.1	2
220	Population vitamin D supplementation in UK adults: too much of nothing?. Drug and Therapeutics Bulletin, 2021, 59, 7-12.	0.3	2
221	Evaluation and Treatment of Primary Hyperparathyroidism. JAMA - Journal of the American Medical Association, 2005, 294, 2699-2700.	7.4	1
222	Osteonecrosis of the jaw and bisphosphonates. BMJ: British Medical Journal, 2006, 333, 1122.3-1123.	2.3	1
223	Vitamin D sufficiency: reply to letter by Heaney. Osteoporosis International, 2007, 18, 835-836.	3.1	1
224	Calcium supplementation does not increase mortality. Medical Journal of Australia, 2008, 189, 55-56.	1.7	1
225	The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women. Obstetrical and Gynecological Survey, 2009, 64, 462-463.	0.4	1
226	Investigating harms in clinical trials - no easy task. International Journal of Clinical Practice, 2010, 64, 1719-1722.	1.7	1
227	Morbidity and mortality in mild primary hyperparathyroidism. Clinical Endocrinology, 2010, 73, 688-688.	2.4	1
228	Reply to RT Chlebowski et al. American Journal of Clinical Nutrition, 2012, 95, 259.	4.7	1
229	Five years of anti-resorptive effects after 1 or 2 doses of zoledronate â€" Data from 2 randomized controlled trials. Bone, 2012, 50, S46-S47.	2.9	1
230	What is the appropriate MHRA regulatory response to calcium's increased cardiovascular risk?. BMJ, The, 2013, 346, f3413-f3413.	6.0	1
231	Observational studiesâ€"just telling us what we want to hear or telling us where we need to look?. Journal of Bone and Mineral Research, 2013, 28, 980-983.	2.8	1
232	Are trials of vitamin D with mortality as an endpoint really needed?. BMJ, The, 2014, 349, g4452-g4452.	6.0	1
233	Benefits of Calcium Supplements Are Too Small for Clinical Equipoise to Exist. Journal of Bone and Mineral Research, 2014, 29, 1914-1915.	2.8	1
234	Vitamin D supplements and bone mineral density â€“ Authors' reply. Lancet, The, 2014, 383, 1293-1294.	13.7	1

#	Article	IF	Citations
235	Republished: Paget's disease of bone: clinical review and update. Postgraduate Medical Journal, 2014, 90, 328-331.	1.8	1
236	Bone density in healthy men after cessation of calcium supplements: 20-month follow-up of a randomized controlled trial. Osteoporosis International, 2015, 26, 173-178.	3.1	1
237	Maintaining Order in Osteoporosis Treatments. Journal of Bone and Mineral Research, 2017, 32, 1147-1147.	2.8	1
238	Are more trials of calcium supplements really needed?. Osteoporosis International, 2017, 28, 2729-2730.	3.1	1
239	Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to prevent fractures in patients with MS; High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology, 2018, 90, 627-628.	1.1	1
240	A closer look at SCOOP: screening for fracture prevention. Lancet, The, 2018, 392, 551-552.	13.7	1
241	Correcting Meta-analyses and Reviews Affected by Retracted Research. JAMA Internal Medicine, 2019, 179, 1005.	5.1	1
242	Evaluating ethics oversight during assessment of research integrity. Research Integrity and Peer Review, 2019, 4, 22.	5.2	1
243	Reporting of absolute risk. BMJ: British Medical Journal, 2010, 341, c6331-c6331.	2.3	1
244	Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ: British Medical Journal, 2010, 341, c6923-c6923.	2.3	1
245	Thyroid ultrasound and nodule malignancy risk: a "real world" assessment of ultrasound reporting and agreement of ultrasound-based malignancy risk estimates with cytology and histology findings. New Zealand Medical Journal, 2020, 133, 20-27.	0.5	1
246	Effective osteoporosis treatments reduce mortality: A meta-analysis. Bone, 2009, 44, S38.	2.9	0
247	Do Calcium Supplements Lead to an Increase in Coronary Calcification?. Heart Lung and Circulation, 2009, 18, S28-S29.	0.4	0
248	Benefits of Vitamin D?. American Journal of Medicine, 2010, 123, e17.	1.5	0
249	Management of primary hyperparathyroidism. Clinical Endocrinology, 2011, 75, 722-722.	2.4	0
250	Vitamin D Supplementation and Fracture Riskâ€"Reply. Archives of Internal Medicine, 2011, 171, 265.	3.8	0
251	Comment: Assessing the Potential Adverse Consequences of Supplemental Calcium on Cardiovascular Outcomes: Should We Change Our Approach to Bone Health?. Annals of Pharmacotherapy, 2012, 46, 1267-1268.	1.9	0
252	Severe Vitamin D Deficiency: A Prerequisite for Chronic Obstructive Pulmonary Disease Responsiveness to Vitamin D Supplementation?. Annals of Internal Medicine, 2012, 156, 904.	3.9	0

#	Article	IF	Citations
253	Low-Dose Zoledronate in Osteopenic Postmenopausal Women. Obstetrical and Gynecological Survey, 2012, 67, 349-350.	0.4	0
254	Effect of osteoporosis treatment on mortality. Bone, 2012, 50, S27.	2.9	0
255	Convicted at a Show Trial. British Journalism Review, 2013, 24, 19-23.	0.0	0
256	Nonsustained hypercalcaemia and primary hyperparathyroidism in the <scp>PEARS</scp> cohort. Clinical Endocrinology, 2013, 79, 899-899.	2.4	0
257	Authors' reply to McCloskey and colleagues. BMJ, The, 2013, 346, f1440-f1440.	6.0	0
258	Authors' reply to MacDonald and Etminan. BMJ, The, 2014, 349, g5523-g5523.	6.0	0
259	Response to letter to editor. Osteoporosis International, 2014, 25, 2501-2501.	3.1	0
260	Correction for Lancet Diabetes Endocrinol 2014; 2: 573â€“80. Lancet Diabetes and Endocrinology,the, 2014, 2, e15.	11.4	0
261	Vitamin D and falls â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2014, 2, 541.	11.4	0
262	Screening for Vitamin D Deficiency. Annals of Internal Medicine, 2015, 162, 736.	3.9	0
263	Neglect or good practice? Authorsâ€™ reply to letters by Rhein and Degner. BMJ: British Medical Journal, 2017, 356, j716.	2.3	0
264	Enough data to draw conclusions about vitamin D and bone health. BMJ: British Medical Journal, 2018, 363, k4755.	2.3	0
265	Author response: Systematic review and statistical analysis of the integrity of 33 randomized controlled trials. Neurology, 2018, 90, 578-578.	1.1	0
266	Decreased thyroid FNA but increased ultrasound: Is the tradeâ€•off worthwhile?. Clinical Endocrinology, 2022, 96, 922-922.	2.4	0
267	Vitamin D Deficiency and Its Health Consequences in New Zealand. , 2010, , 589-601.		0
268	Calcium and cardiovascular risks. Australian Prescriber, 2013, 36, 148-149.	1.0	0
269	Diagnostic category agreement and malignancy rates in clinician-categorised, non-standardised thyroid cytology reports. New Zealand Medical Journal, 2014, 127, 49-55.	0.5	0
270	Participant injury in clinical trials conducted in New Zealand for the benefit of manufacturers: an unfair system?. New Zealand Medical Journal, 2021, 134, 124-131.	0.5	0

#	Article	IF	Citations
271	Vitamin D deficiency, supplementation and testing: have we got it right in New Zealand?. New Zealand Medical Journal, 2021, 134, 86-95.	0.5	0
272	Nonoperative Management of Mild Primary Hyperparathyroidism: A Reasonable, Evidence-Based Option. Annals of Internal Medicine, 2022, , .	3.9	0